Catalin Toma, MD, Presents Positive Results for Patients with Pulmonary Embolism at Transcatheter Cardiovascular Therapeutics Connect Virtual Symposium
January 14, 2021
Director of interventional cardiology at the UPMC Heart and Vascular Institute and national principal investigator in the FLASH study, Catalin Toma, MD, reported that 98.7% of the first 230 patients who underwent a FlowTriever® thrombectomy reached the 48-hour post-operation benchmark without experiencing any major adverse event. The study also found a statistically significant improvement on acute hemodynamics, procedural measures, 48-hour all-cause mortality, and longer-term patient outcomes.
The FlowTriever® All-Comer Registry for Patient Safety and Hemodynamics (FLASH) is designed to evaluate the safety and effectiveness of the FlowTriever® System for use in the remove of emboli from the pulmonary arteries in the treatment of pulmonary embolism (PE). The largest prospective hemodynamic study of any PE treatment ever undertaken, FLASH also represents the first major all comers study of the mechanical approach to PE. The registry includes 500 participants from 19 sites across the United States.
Dr. Toma presented these results at the Transcatheter Cardiovascular Therapeutics (TCC) Connect virtual symposium on Wednesday Oct. 18, 2020.
If you missed Dr. Toma’s presentation of the study results, you can view it on the TCT conference website here.
